KIMIABL
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Kimia Biosciences Says Rakesh Chetani Resigns As CFO
April 23 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
RAKESH CHETANI RESIGNS AS CFO
Source text: ID:nBSEnR9nM
Further company coverage: KIMI.BO
(([email protected];;))
April 23 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
RAKESH CHETANI RESIGNS AS CFO
Source text: ID:nBSEnR9nM
Further company coverage: KIMI.BO
(([email protected];;))
Kimia Biosciences Gets Order Worth $200,000
Sept 16 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES LTD - GETS ORDER WORTH $200,000
Source text for Eikon: ID:nBSE4ZHdnT
Further company coverage: KIMI.BO
(([email protected];))
Sept 16 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES LTD - GETS ORDER WORTH $200,000
Source text for Eikon: ID:nBSE4ZHdnT
Further company coverage: KIMI.BO
(([email protected];))
Kimia Biosciences Says Filed Quality Product For API, Benfotiamine In European Union In Bulgaria
Aug 9 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES - FILED QUALITY PRODUCT FOR API, BENFOTIAMINE IN EUROPEAN UNION IN BULGARIA
Further company coverage: KIMI.BO
(([email protected];))
Aug 9 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES - FILED QUALITY PRODUCT FOR API, BENFOTIAMINE IN EUROPEAN UNION IN BULGARIA
Further company coverage: KIMI.BO
(([email protected];))
Kimia Biosciences Gets Confirmation For Active Substances Imported Into EU For Medical Products From India Govt
April 10 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES - GETS CONFIRMATION FOR ACTIVE SUBSTANCES IMPORTED INTO EUROPEAN UNION FOR MEDICAL PRODUCTS FROM INDIA GOVERNMENT
Source text for Eikon: ID:nBSE3sN0jG
Further company coverage: KIMI.BO
(([email protected];))
April 10 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
KIMIA BIOSCIENCES - GETS CONFIRMATION FOR ACTIVE SUBSTANCES IMPORTED INTO EUROPEAN UNION FOR MEDICAL PRODUCTS FROM INDIA GOVERNMENT
Source text for Eikon: ID:nBSE3sN0jG
Further company coverage: KIMI.BO
(([email protected];))
Kimia Biosciences Receives Written Confirmation For Active Substances Imported Into European Union
March 4 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
RECEIVED WRITTEN CONFIRMATION FOR ACTIVE SUBSTANCES IMPORTED INTO EUROPEAN UNION
Source text for Eikon: ID:nBSE6CgXyR
Further company coverage: KIMI.BO
(([email protected];))
March 4 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
RECEIVED WRITTEN CONFIRMATION FOR ACTIVE SUBSTANCES IMPORTED INTO EUROPEAN UNION
Source text for Eikon: ID:nBSE6CgXyR
Further company coverage: KIMI.BO
(([email protected];))
Kimia Biosciences Says Co Has Withdrawn Entire Contribution Of 51% From Magnizent Biochem LLP
Dec 29 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
CO HAS WITHDRAWN ENTIRE CONTRIBUTION OF 51% FROM MAGNIZENT BIOCHEM LLP
Source text for Eikon: ID:nBSE40n4cV
Further company coverage: KIMI.BO
(([email protected];))
Dec 29 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
CO HAS WITHDRAWN ENTIRE CONTRIBUTION OF 51% FROM MAGNIZENT BIOCHEM LLP
Source text for Eikon: ID:nBSE40n4cV
Further company coverage: KIMI.BO
(([email protected];))
Kimia Biosciences Appointed Rakesh Chetani As Chief Financial Officer
Sept 7 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
APPOINTED RAKESH CHETANI AS CHIEF FINANCIAL OFFICER
CFO LAKSHAY PRAKASH RESIGNS
Further company coverage: KIMI.BO
(([email protected];))
Sept 7 (Reuters) - Kimia Biosciences Ltd KIMI.BO:
APPOINTED RAKESH CHETANI AS CHIEF FINANCIAL OFFICER
CFO LAKSHAY PRAKASH RESIGNS
Further company coverage: KIMI.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Kimia Biosciences do?
Laurel Organics Ltd. is a Public limited company specializing in the manufacturing of over thirty intermediates for various medical fields including Cardiovascular, Diabetes, and Dermatology.
Who are the competitors of Kimia Biosciences?
Kimia Biosciences major competitors are Coral Laboratories, Alpa Lab, Murae Organisor, Krebs Biochem.&Inds, Panchsheel Organics, Ambalal Sarabhai Ent, Balaxi Pharma.. Market Cap of Kimia Biosciences is ₹225 Crs. While the median market cap of its peers are ₹209 Crs.
Is Kimia Biosciences financially stable compared to its competitors?
Kimia Biosciences seems to be less financially stable compared to its competitors. Altman Z score of Kimia Biosciences is 2.18 and is ranked 7 out of its 8 competitors.
Does Kimia Biosciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Kimia Biosciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Kimia Biosciences allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Kimia Biosciences balance sheet?
Balance sheet of Kimia Biosciences is moderately strong, But short term working capital might become an issue for this company.
Is the profitablity of Kimia Biosciences improving?
Yes, profit is increasing. The profit of Kimia Biosciences is ₹9.42 Crs for TTM, -₹5.31 Crs for Mar 2024 and -₹9.35 Crs for Mar 2023.
Is the debt of Kimia Biosciences increasing or decreasing?
The net debt of Kimia Biosciences is decreasing. Latest net debt of Kimia Biosciences is ₹31.89 Crs as of Mar-25. This is less than Mar-24 when it was ₹42.48 Crs.
Is Kimia Biosciences stock expensive?
Kimia Biosciences is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Kimia Biosciences is 23.38, while 3 year average PE is 15.59. Also latest EV/EBITDA of Kimia Biosciences is 0 while 3yr average is 1050.
Has the share price of Kimia Biosciences grown faster than its competition?
Kimia Biosciences has given lower returns compared to its competitors. Kimia Biosciences has grown at ~16.02% over the last 5yrs while peers have grown at a median rate of 18.93%
Is the promoter bullish about Kimia Biosciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Kimia Biosciences is 74.94% and last quarter promoter holding is 74.94%.
Are mutual funds buying/selling Kimia Biosciences?
The mutual fund holding of Kimia Biosciences is stable. The current mutual fund holding in Kimia Biosciences is 0.38% while previous quarter holding is 0.38%.